|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-6-2
|
|
pubmed:abstractText |
Rituximab 375 mg/m(2) weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50 x 10(9)/L) and complete responses (platelet count > 100 x 10(9)/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:AvanziniMaria AntoniettaMA,
pubmed-author:BaccaraniMicheleM,
pubmed-author:BattistaMarta LisaML,
pubmed-author:BocchiaMonicaM,
pubmed-author:CavallinMargheritaM,
pubmed-author:DefinaMarziaM,
pubmed-author:FaninRenatoR,
pubmed-author:FerraraFelicettoF,
pubmed-author:IppolitiMicaelaM,
pubmed-author:IsolaMiriamM,
pubmed-author:MarinLucianaL,
pubmed-author:MeugnierMM,
pubmed-author:MontagnaMichelaM,
pubmed-author:PalmieriSalvatoreS,
pubmed-author:PirrottaMaria TeresaMT,
pubmed-author:RegazziMarioM,
pubmed-author:SoldanoFrancaF,
pubmed-author:VianelliNicolaN,
pubmed-author:ZajaFrancescoF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
930-3
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18403395-Adolescent,
pubmed-meshheading:18403395-Adult,
pubmed-meshheading:18403395-Aged,
pubmed-meshheading:18403395-Antibodies, Monoclonal,
pubmed-meshheading:18403395-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18403395-B-Lymphocytes,
pubmed-meshheading:18403395-Disease-Free Survival,
pubmed-meshheading:18403395-Female,
pubmed-meshheading:18403395-Humans,
pubmed-meshheading:18403395-Immunologic Factors,
pubmed-meshheading:18403395-Male,
pubmed-meshheading:18403395-Middle Aged,
pubmed-meshheading:18403395-Platelet Count,
pubmed-meshheading:18403395-Purpura, Thrombocytopenic, Idiopathic,
pubmed-meshheading:18403395-Time Factors,
pubmed-meshheading:18403395-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
|
|
pubmed:affiliation |
Clinica Ematologica, Azienda Ospedaliera Universitaria, piazza S. Maria della Misericordia, 33100 Udine, Italy. zaja.francesco@aoud.sanita.fvg.it
|
|
pubmed:publicationType |
Journal Article
|
